Scios Inc.

Scios Nova, Inc.

Other

California Biotechnology Inc.

Children's Medical Center Corporation

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Judith A Abraham

John C Fiddes

Andrew Asher Protter

W Michael Kavanaugh

Michael Klagsbrun

Anne B Jefferson

N Stephen Pollitt

Shigeki Higashiyama

Edmund G Tischer

Gail E Besner

Richard L Mitchell

Siew C Schleyer

Stewart A Thompson

This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.

Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers

The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.

Recombinant fibroblast growth factor analogs

The invention is directed to a method of enhancing the biological activity of vascular endothelial growth factors (VEGF). The invention further concerns certain VEGF variants having enhanced biological activity, methods and means for preparing these variants, and pharmaceutical compositions comprising them. In a further aspect, the invention concerns methods of treatment using, and articles of manufacture containing such VEGF variants.

Vascular endothelial growth factor variants

Human basic fibroblast growth factor analog

Disclosed are heparin binding mitogens which include an epidermal growth factor-homologous segment (HB-EHM). These factors stimulate proliferation of fibroblast cells, epithelial cells, and smooth muscle cells, but not endothelial cells. Also disclosed are isolated antibodies that recognize, and purified nucleic acids that encode, the above growth factors as well as isolated polypeptides, vectors containing such nucleic acids, and cells harboring such vectors. Growth factors of this invention may be used for accelerating the rate of wound healing, for the in vitro culture of HB-EHM-responsive cells, and for the identification of antagonists to HB-EHM.

Heparin binding mitogen with homology to epidermal growth factor (EGF)

The DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting wound healing and related tissue repair.

Recombinant human basic fibroblast growth factor

Disclosed herein are the DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF). Expression of these sequences results in practical amounts of proteins useful in effecting wound healing.

Methods of producing recombinant fibroblast growth factors

DNA encoding human recombinant basic fibroblast growth factor

Isolated DNA sequences, expression vectors and transformant cells are provided which allow for the large scale production of vascular endothelial cell growth factor. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.

DNA sequences encoding bVEGF120 and hVEGF121 and methods for the

There is described an isolated vascular endothelial cell growth factor selected from the group consisting of bovine vascular endothelial cell growth factor of 120 amino acids and human vascular endothelial cell growth factor of 121 amino acids. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.

Production of vascular endothelial cell growth factor

DNA sequences are provided which encode a form of basic fibroblast growth factor lacking one of the alanine residues immediately following the N-terminal methionine residue of the primary translation product. The DNA sequences can be expressed to produce basic fibroblast growth factor having a homogeneous N-terminus.

Growing community of inventors

San Jose, CA, United States of America

Judith A Abraham